Kymera Therapeutics Inc (KYMR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 47,072 | 78,592 | 46,826 | 72,832 | 34,034 |
| Gross Profit | 47,072 | 78,592 | 46,826 | 72,832 | 34,034 |
| Operating Expenses | 308,707 | 244,122 | 208,082 | 173,362 | 80,338 |
| Operating Income | -261,635 | -165,530 | -161,256 | -100,530 | -46,304 |
| Interest Expense | 249 | 196 | 176 | 175 | 115 |
| Other Income | 38,026 | 18,764 | 6,624 | 488 | 826 |
| Pre-tax Income | -223,858 | -146,962 | -154,808 | -100,217 | -45,593 |
| Net Income Continuous | -223,858 | -146,962 | -154,808 | -100,217 | -45,593 |
| Net Income | $-223,858 | $-146,962 | $-154,808 | $-100,217 | $-45,593 |
| EPS Basic Total Ops | -2.98 | -2.52 | -2.87 | -2.09 | -3.15 |
| EPS Basic Continuous Ops | -2.98 | -2.52 | -2.87 | -2.09 | -2.63 |
| EPS Diluted Total Ops | -2.98 | -2.52 | -2.87 | -2.09 | -3.15 |
| EPS Diluted Continuous Ops | -2.98 | -2.52 | -2.87 | -2.09 | -2.63 |
| EPS Diluted Before Non-Recurring Items | -2.98 | -2.52 | -2.87 | -2.09 | -3.15 |
| EBITDA(a) | $-268,245 | $-167,194 | $-157,390 | $-92,326 | $-42,970 |